Citius Pharmaceuticals, Inc. Cost of Revenue
Citius Pharmaceuticals, Inc. (CTXR) reported Cost of Revenue of $491.84 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. cost of revenue for the quarter ending 2026-06-30 was $491.84K.
- Citius Pharmaceuticals, Inc. cost of revenue for the quarter ending 2026-03-31 was $328.88K.
- Citius Pharmaceuticals, Inc. cost of revenue for the quarter ending 2025-12-31 was $789.21K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month |
|---|---|---|---|
| 2026-06-30 | $491.84K 10-Q · filed 2026-08-14 | $820.72K derived: sum of 2 quarters · filed 2026-08-14 | $1.61M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $328.88K 10-Q · filed 2026-05-15 | $1.12M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $789.21K 10-Q · filed 2026-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |